SIGA CEO Phil Gomez, PhD, to Present on Smallpox and Orthopox Preparedness at NATO Chemical, Biological, Radiological & Nuclear Medical Symposium

Inaugural meeting on June 28-30, 2023, to include updates from leading experts on strategies to plan for and address broad range of potential global health risks including biological and viral disease outbreaks.

NEW YORK, June 27, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that SIGA CEO Phil Gomez, PhD, will present an overview of the role of therapeutics in global planning and response to potential outbreaks of smallpox and other orthopox viruses during the upcoming NATO Chemical, Biological, Radiological & Nuclear Medical Symposium in Oak Ridge, Tennessee. His presentation, entitled “Therapeutics role in smallpox and orthopox virus preparedness”, will be held on Thursday June 29^th at 2:20 PM ET.

“We are very pleased that this important inaugural NATO Symposium will include a focus on biological health risks including smallpox and other orthopox viruses, which require both careful preparation including stockpiling available and proven-effective treatments as well as the ability to mobilize and respond rapidly to emerging threats,” said Phil Gomez, CEO of SIGA. “SIGA is actively responding to global efforts to stockpile therapies to treat smallpox, mpox and other orthopox viruses. In just one example, we are currently preparing for a $112.5 million order for oral TPOXX in the third quarter by the U.S. Department of Health and Human Services that we expect to be delivered this year to the U.S. Strategic National Stockpile.   In addition, SIGA has been proactively building inventory in our supply chain to enable a response to additional demand given the evolving threat landscape for othropoxviruses. We believe that participation in events such as the symposium, in conjunction with stockpiling activities by the U.S. government, will increasingly encourage governments around the world to focus on strategies to prepare for smallpox and other orthopox virus outbreaks.”

ABOUT SIGA TECHNOLOGIES, INC. and TPOXX

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness. Our lead product is TPOXX, also known as tecovirimat and ST-246, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the US maintains a supply of TPOXX under Project BioShield. The oral formulation of TPOXX was approved by the FDA for the treatment of smallpox in 2018, and the IV formulation was approved for the same indication in 2022. The full label is available by clicking here. Oral tecovirimat received approval from the European Medicines Agency (EMA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom in 2022. The EMA and UK approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox. The full label is available by clicking here. In September 2018, SIGA signed a contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, for additional procurement and development related to both oral and intravenous formulations of TPOXX. For more information about SIGA, please visit www.siga.com.